United Therapeutics Corporation $UTHR Stock: Intech Investment Management LLC Decreases Stake

Intech Investment Management LLC decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 18.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,769 shares of the biotechnology company’s stock after selling 5,333 shares during the quarter. Intech Investment Management LLC owned approximately 0.06% of United Therapeutics worth $12,880,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in United Therapeutics in the 2nd quarter worth $2,868,735,000. Janus Henderson Group PLC lifted its position in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares in the last quarter. Jupiter Topco LLC purchased a new position in shares of United Therapeutics in the second quarter valued at about $450,140,000. Bank of New York Mellon Corp bought a new position in shares of United Therapeutics in the second quarter worth about $159,522,000. Finally, Caisse de depot et placement du Quebec bought a new position in shares of United Therapeutics in the second quarter worth about $154,304,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.6%

Shares of UTHR stock opened at $587.88 on Tuesday. The stock has a market cap of $25.04 billion, a P/E ratio of 22.18, a PEG ratio of 3.94 and a beta of 0.49. United Therapeutics Corporation has a 52 week low of $455.63 and a 52 week high of $614.23. The company’s fifty day simple moving average is $544.61 and its two-hundred day simple moving average is $536.98.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the company earned $7.16 EPS. On average, analysts anticipate that United Therapeutics Corporation will post 25.08 EPS for the current fiscal year.

United Therapeutics declared that its board has approved a share repurchase plan on Thursday, October 22nd that permits the company to repurchase $2 billion in shares. This buyback authorization permits the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Royal Bank Of Canada increased their target price on United Therapeutics from $697.00 to $725.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. The Goldman Sachs Group reissued a “sell” rating and issued a $368.00 price target on shares of United Therapeutics in a report on Thursday, October 15th. Raymond James Financial set a $720.00 price target on United Therapeutics in a report on Wednesday, November 4th. UBS Group set a $725.00 price target on United Therapeutics in a research note on Monday, October 19th. Finally, Wells Fargo & Company increased their price objective on shares of United Therapeutics from $700.00 to $703.00 and gave the company an “overweight” rating in a report on Thursday, November 5th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $676.40.

Read Our Latest Stock Analysis on United Therapeutics

Insider Buying and Selling

In related news, Director Christopher Patusky sold 1,210 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $580.00, for a total transaction of $701,800.00. Following the completion of the transaction, the director directly owned 2,140 shares of the company’s stock, valued at approximately $1,241,200. This represents a 36.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $592.42, for a total value of $5,627,990.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $192,206,522.06. This represents a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 412,238 shares of company stock worth $221,790,391. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

(Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

See Also

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.